TriviumVet’s Omeprazole product receives positive CVMP opinion.
20th February
On the 13th of February 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Omeprazole TriviumVet, gastro-resistant capsule, intended for dogs.
On the basis of quality, safety and efficacy data submitted, the Committee for Medical Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) recommended Omeprazole TriviumVet for marketing authorisation in the European Union.
This is a novel medication indicated as an aid in the treatment of NSAID-induced gastric ulceration in dogs. This is closing a treatment gap for a previously unmet need.